Trial Tests CRISPR Gene-Editing to Treat Sickle Cell Disease

WEDNESDAY, July 31, 2019 (HealthDay News) -- A U.S. clinical trial of CRISPR gene-editing to treat people with sickle cell disease is underway.

It seeks to recruit up to 45 adults with severe sickle cell disease, a group of inherited blood disorders, CNN reported.

Sickle cell disease can cause pain, anemia, blindness, organ damage and shorten a person's life.

The trial will use CRISPR in an attempt to boost production of a different kind of hemoglobin (fetal hemoglobin) that makes it harder for cells to sickle and stick together, CNN reported.

Sickle cell disease affects about 100,000 Americans, most of African ancestry or identifying as black.

MedicalNews
Copyright © 2019 HealthDay. All rights reserved.

QUESTION

Sickle cell disease is named after a farming tool. See Answer

Health Solutions From Our Sponsors

CONTINUE SCROLLING FOR RELATED SLIDESHOW